导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 15.00% | 463/4773 |
| 近一周 | -2.78% | 3066/5462 |
| 近一月 | -3.07% | 1541/5421 |
| 近一季 | -5.19% | 1784/5209 |
| 近半年 | 2.27% | 978/4920 |
| 近一年 | 22.04% | 356/4366 |
| 近两年 | 95.51% | 639/2954 |
| 近三年 | 61.99% | 415/2253 |
| 成立以来 | 51.04% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
4.68% 486/4961 |
22.52% 1125/5312 |
- - |
- - |
| 2025 | 33.81% 1093/4813 |
2.08% 1473/3635 |
5.58% 565/4076 |
20.87% 1905/4524 |
2.71% 870/4813 |
| 2024 | 8.99% 1499/3463 |
-0.74% 1140/2808 |
-4.45% 1510/3014 |
13.47% 2163/3129 |
1.27% 1094/3463 |
| 2023 | -3.77% 650/2656 |
6.96% 623/2280 |
-4.59% 1214/2385 |
-2.61% 701/2515 |
-3.17% 619/2655 |
| 2022 | -18.95% 780/2207 |
-12.36% 605/1919 |
4.16% 1049/2016 |
-10.32% 381/2113 |
-1.00% 1666/2208 |
| 2021 | 16.37% 269/1822 |
-1.14% 437/1255 |
12.87% 304/1330 |
4.55% 337/1466 |
-0.25% 1217/1822 |
| 2020 | - - |
- - |
- - |
- - |
- - |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 广发中证500指数增强A VS. 长安沪深300非周期A(740101) |